Authors
Latest:
Lessons Learned and Future Possibilities in ALS Collaborations: Edritz Javelosa, PhDAt the 2023 MDA conference, the scientific research portfolio director at Muscular Dystrophy Association detailed a session on collaborative research in ALS and ongoing efforts in the field. [WATCH TIME: 3 minutes]
Latest:
Prescribing Psychical Activity Regimens in Spinal Muscular Atrophy: Jacqueline Montes, PT, EdDThe associate professor of rehabilitation and regenerative medicine at Columbia University Medical Center discussed the ways clinicians go about properly prescribing exercise regimens for patients with spinal muscular atrophy. [WATCH TIME: 3 minutes]
Latest:
The Evolving Impact of Biosimilars and Pharmacists When Treating Multiple Sclerosis: Ryan Haumschild, PharmD, MS, MBAThe director of pharmacy at Emory Healthcare and Winship Cancer Institute talked about the role of pharmacists in multiple sclerosis patient care and collaborating with providers as biosimilars become available. [WATCH TIME: 5 minutes]
Latest:
Redefining the Understanding of Alzheimer Disease and Its Pathology: Ralph Nixon, MD, PhDThe professor of psychiatry and cell biology at NYU Langone provided commentary on new findings which challenge traditional theories on the root of Alzheimer disease and how it is targeted. [WATCH TIME: 17 minutes]
Latest:
Advancing MS Care for Minority Populations Using the VISIBL-MS Bilingual Framework: Jaime Imitola, MDThe chief of the Division of MS and Neuroimmunology at UConn Health talked about the unevenly distributed progress in multiple sclerosis care, impacting minority populations who often face worse disease outcomes. [WATCH TIME: 6 minutes]
Latest:
Advanced Imaging for Extended Stroke TreatmentWith many patients presenting with an unknown time of last known well, establishing a tissue window using advanced imaging techniques may allow for more effective intervention and better outcomes.
Latest:
How Surgical Interventions Improve Survival Rate in Pediatric Epilepsy: Sandi K. Lam, MD, MBAThe division chief of pediatric neurosurgery at Ann & Robert H. Lurie Children's Hospital of Chicago talked about findings from a recently published study on long-term survival of pediatric patients with drug-resistant epilepsy which was presented at AES 2023. [WATCH TIME: 6 minutes]
Latest:
Mechanistic Potential of Pepinemab, a SEMA4D-Blocking Antibody: Terrence L. Fisher, PhDThe senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]
Latest:
Monitoring Progression in Multiple Sclerosis: Stephen Rao, PhD, ABPP-CnThe Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his investigations into improving the MSPT.
Latest:
Expanding Knowledge, Treatment Options on Excessive Daytime Sleepiness: Paula K. Schweitzer, PhDThe director of research at St. Luke’s Sleep Medicine and Research Center discussed the current treatment landscape for excessive daytime sleepiness and how solriamfetol plays a role.
Latest:
Paradigm Shift In Non-Motor Symptom Management in Parkinson’s DiseaseThe expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.
Latest:
Discussing Preventative Migraine Lifestyle Changes with PatientsDr Andrew Charles shares how he eases patient anxieties over lifestyle changes for preventive migraine therapy.
Latest:
Early Monitoring and Treatment for Bone Health in Duchenne Muscular Dystrophy: Meilan Rutter, MDAt the 2023 MDA conference, a pediatric endocrinologist from Cincinnati Children’s Hospital talked about the unmet needs in treating bone health for patients with Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]
Latest:
Emerging Approaches to the Treatment of Multiple SclerosisExperts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
Latest:
Promising Disease-Modifying Therapies in Parkinson DiseaseDespite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Latest:
AUPN Leadership Minute Episode 13: Principles of Making a Business CaseEpisode 13 of the AUPN Leadership Minute features Muhammad “Mud” Alvi, MD, of West Virginia University; and Barbara G. Vickrey, MD, MPH, of Icahn School of Medicine at Mount Sinai. [WATCH TIME: 4 minutes]
Latest:
Reviewing the Phase 2 OVERTURE Results of Gamma Sensory Stimulation Device: Brent VaughanThe chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]
Latest:
Future Implications, Outlook of New CDC Developmental Milestone Guidelines: Paul Lipkin, MDThe director of medical outpatient services at the Kennedy Krieger Institute discussed the long-term effects of the updated developmental milestone guidelines and the need to judge children based on the 75th percentile. [WATCH TIME: 7 minutes]
Latest:
Changes in Vocation as Early Signs for Alzheimer Disease, Cognitive Issues: Alvaro Pascual-Leone, MD, PhDThe chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]
Latest:
A Call for Urgent Action to Redefine Stroke Protocols: Stephan A. Mayer, MD, FCCM, FNCSThe director of neurocritical care and emergency neurology services at Westchester Medical Center Health System talked about a recently published paper that highlighted the need to address the disparity in quality metrics for stroke care, especially for intracerebral hemorrhage. [WATCH TIME: 4 minutes]
Latest:
Next Steps in Tackling CDKL5 Deficiency Disorder Following First Approval: Elia Pestana-Knight, MDThe pediatric epileptologist from Cleveland Clinic provided commentary on the changes needed to improve research and drug development in CDKL5 deficiency disorder, as well as the organizations committed to advancing the state of care. [WATCH TIME: 3 minutes]
Latest:
Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MDThe medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]
Latest:
Expanding Neuropalliative Care to New Disease States: Benzi Kluger, MD, MSThe president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]
Latest:
Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud MaromThe president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
Latest:
Not Your Grandmother’s Dopamine: PMD Alliance Releases On-Demand CME Topics in Advanced Therapeutics in Movement-Related DisordersThe PMD Alliance has developed a group of 6 on-demand CME events and live panel discussions, in partnership with MedStar Georgetown University Hospital, taking place on October 23-24, 2021, developed and presented by Yasar Torres-Yaghi, MD , and Fernando Pagan, MD.
Latest:
Capabilities of Deep Brain Stimulation to Modulate Late-Stage Neuroplasticity: Kenneth Baker, PhDThe associate staff member in the department of neurology at Cleveland Clinic discussed the major take-home points and post-hoc findings from a positive study of deep brain stimulation in poststroke patients. [WATCH TIME: 3 minutes]
Latest:
FDA to Add Warning Related to Guillain-Barré Syndrome on Johnson & Johnson VaccineSince vaccine administration, the CDC has announced 100 preliminary cases of Guillain-Barré syndrome.
